Sally Peprah1, Martin D Ogwang2, Patrick Kerchan3, Steven J Reynolds4, Constance N Tenge5,6, Pamela A Were5,6, Robert T Kuremu5,6, Walter N Wekesa5,6, Nestory Masalu7, Esther Kawira8, Isaac Otim2, Ismail D Legason3, Leona W Ayers9, Kishor Bhatia1, James J Goedert1, Ruth M Pfeiffer1, Sam M Mbulaiteye10. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Infections and Immunoepidemiology Branch, 9609 Medical Center Dr, Rm. 6E-118, MSC 3330, Bethesda, MD, 20892, USA. 2. EMBLEM Study, St. Mary's Hospital, Lacor, Gulu & African Field Epidemiology Network, Kampala, Uganda. 3. EMBLEM Study, Kuluva Hospital, Arua & African Field Epidemiology Network, Kampala, Uganda. 4. Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. 5. EMBLEM Study, Moi University College of Health Sciences, Eldoret, Kenya. 6. Moi Teaching and Referral Hospital (MTRH), Academic Model Providing Access To Healthcare (AMPATH), Eldoret, Kenya. 7. EMBLEM Study, Bugando Medical Center, Mwanza, Tanzania. 8. EMBLEM Study, Shirati Health and Educational Foundation, Shirati, Tanzania. 9. Department of Pathology, The Ohio State University, Columbus, OH, USA. 10. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Infections and Immunoepidemiology Branch, 9609 Medical Center Dr, Rm. 6E-118, MSC 3330, Bethesda, MD, 20892, USA. mbulaits@mail.nih.gov.
Abstract
BACKGROUND: Falciparum and endemic Burkitt lymphoma (eBL) are co-endemic in Africa, but the malaria experience in eBL patients is unknown. A lower prevalence of falciparum has been reported in eBL patients, but those results are anecdotally attributed to pre-enrollment anti-malaria treatment. METHODS: We studied 677 eBL patients and 2920 community controls aged 0-15 years enrolled in six regions in Uganda, Tanzania, and Kenya during 2010-2016. Falciparum was diagnosed using thick blood film microscopy (TFM) and antigen-capture rapid diagnostic tests (RDTs). Guardians of the children answered a 40-item structured questionnaire about their child's pre-enrollment lifetime malaria history and treatment, demographics, socioeconomics, animal exposures, fevers, and hospitalizations. We utilized exploratory factor analysis to reduce the 40 questionnaire variables into six factors, including Inpatient malaria and Outpatient malaria factors that were surrogates of pre-enrollment anti-malaria treatment. The six factors accounted for 83-90% of the variance in the questionnaire data. We calculated odds ratios and 95% confidence intervals (OR 95% CI) of association of eBL with falciparum positivity, defined as positive both on TFM or RDTs, or only RDTs (indicative of recent infection) or TFM (indicative of current falciparum infection) versus no infection, using multivariable logistic regression, controlling for group of age (0-2, 3-5, 6-8, 9-11 and 12-15 years), sex, and study site and the afore-mentioned pre-enrollment factors. RESULTS: The prevalence of falciparum infection was 25.6% in the eBL cases and 45.7% in community controls (aOR = 0.43, 95% CI: 0.40, 0.47; P < 0.0001). The results were similar for recent falciparum infection (6.9% versus 13.5%, aOR = 0.44, 95% CI: 0.38, 0.50; P < 0.0001) and current falciparum infection (18.7% versus 32.1%, aOR = 0.47, 95% CI: 0.43, 0.51; P < 0.0001). These aORs for any, recent and current falciparum infection did not change when we adjusted for pre-enrollment factors (aORs = 0.46, =0.44, and = 0.51, respectively) were significantly lower in stratified analysis for any infection in children < 5 years (aOR = 0.46; 95% CI: 0.29, 0.75) or ≥ 10 years (aOR = 0.47; 95% CI: 0.32, 0.71). CONCLUSION: Our study results reduce support for pre-enrollment antimalaria treatment as a sole explanation for the observed lower falciparum prevalence in eBL cases and open a space to consider alternative immunology-based hypotheses.
BACKGROUND: Falciparum and endemic Burkitt lymphoma (eBL) are co-endemic in Africa, but the malaria experience in eBL patients is unknown. A lower prevalence of falciparum has been reported in eBL patients, but those results are anecdotally attributed to pre-enrollment anti-malaria treatment. METHODS: We studied 677 eBL patients and 2920 community controls aged 0-15 years enrolled in six regions in Uganda, Tanzania, and Kenya during 2010-2016. Falciparum was diagnosed using thick blood film microscopy (TFM) and antigen-capture rapid diagnostic tests (RDTs). Guardians of the children answered a 40-item structured questionnaire about their child's pre-enrollment lifetime malaria history and treatment, demographics, socioeconomics, animal exposures, fevers, and hospitalizations. We utilized exploratory factor analysis to reduce the 40 questionnaire variables into six factors, including Inpatient malaria and Outpatientmalaria factors that were surrogates of pre-enrollment anti-malaria treatment. The six factors accounted for 83-90% of the variance in the questionnaire data. We calculated odds ratios and 95% confidence intervals (OR 95% CI) of association of eBL with falciparum positivity, defined as positive both on TFM or RDTs, or only RDTs (indicative of recent infection) or TFM (indicative of current falciparum infection) versus no infection, using multivariable logistic regression, controlling for group of age (0-2, 3-5, 6-8, 9-11 and 12-15 years), sex, and study site and the afore-mentioned pre-enrollment factors. RESULTS: The prevalence of falciparum infection was 25.6% in the eBL cases and 45.7% in community controls (aOR = 0.43, 95% CI: 0.40, 0.47; P < 0.0001). The results were similar for recent falciparum infection (6.9% versus 13.5%, aOR = 0.44, 95% CI: 0.38, 0.50; P < 0.0001) and current falciparum infection (18.7% versus 32.1%, aOR = 0.47, 95% CI: 0.43, 0.51; P < 0.0001). These aORs for any, recent and current falciparum infection did not change when we adjusted for pre-enrollment factors (aORs = 0.46, =0.44, and = 0.51, respectively) were significantly lower in stratified analysis for any infection in children < 5 years (aOR = 0.46; 95% CI: 0.29, 0.75) or ≥ 10 years (aOR = 0.47; 95% CI: 0.32, 0.71). CONCLUSION: Our study results reduce support for pre-enrollment antimalaria treatment as a sole explanation for the observed lower falciparum prevalence in eBL cases and open a space to consider alternative immunology-based hypotheses.
Authors: Lucy M Carpenter; Robert Newton; Delphine Casabonne; John Ziegler; Sam Mbulaiteye; Edward Mbidde; Henry Wabinga; Harold Jaffe; Valerie Beral Journal: Int J Cancer Date: 2008-03-15 Impact factor: 7.396
Authors: Peter Aka; Maria Candida Vila; Amar Jariwala; Francis Nkrumah; Benjamin Emmanuel; Masanori Yagi; Nirianne Marie Q Palacpac; Maria V Periago; Janet Neequaye; Christine Kiruthu; Takahiro Tougan; Paul H Levine; Robert J Biggar; Ruth M Pfeiffer; Kishor Bhatia; Toshihiro Horii; Jeffrey M Bethony; Sam M Mbulaiteye Journal: Blood Date: 2013-05-03 Impact factor: 22.113
Authors: Davide F Robbiani; Stephanie Deroubaix; Niklas Feldhahn; Thiago Y Oliveira; Elsa Callen; Qiao Wang; Mila Jankovic; Israel T Silva; Philipp C Rommel; David Bosque; Tom Eisenreich; André Nussenzweig; Michel C Nussenzweig Journal: Cell Date: 2015-08-13 Impact factor: 41.582
Authors: Ismail D Legason; Ruth M Pfeiffer; Krizia-Ivana Udquim; Andrew W Bergen; Mateus H Gouveia; Samuel Kirimunda; Isaac Otim; Eric Karlins; Patrick Kerchan; Hadijah Nabalende; Ariunaa Bayanjargal; Benjamin Emmanuel; Paul Kagwa; Ambrose O Talisuna; Kishor Bhatia; Meredith Yeager; Robert J Biggar; Leona W Ayers; Steven J Reynolds; James J Goedert; Martin D Ogwang; Joseph F Fraumeni; Ludmila Prokunina-Olsson; Sam M Mbulaiteye Journal: EBioMedicine Date: 2017-10-03 Impact factor: 8.143
Authors: Andriy Derkach; Isaac Otim; Ruth M Pfeiffer; Olusegun O Onabajo; Ismail D Legason; Hadijah Nabalende; Martin D Ogwang; Patrick Kerchan; Ambrose O Talisuna; Leona W Ayers; Steven J Reynolds; Francis Nkrumah; Janet Neequaye; Kishor Bhatia; Thor G Theander; Ludmila Prokunina-Olsson; Louise Turner; James J Goedert; Thomas Lavstsen; Sam M Mbulaiteye Journal: EBioMedicine Date: 2018-12-20 Impact factor: 8.143
Authors: Charles Torgbor; Peter Awuah; Kirk Deitsch; Parisa Kalantari; Karen A Duca; David A Thorley-Lawson Journal: PLoS Pathog Date: 2014-05-29 Impact factor: 6.823